CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DE L’IRINOTECAN

Précédent Retour au menu principal  Suivant


référence

chimiothérapie

n

(stIV)

% RO

p

SM

p

Negoro,

2003 (1)

I. CDDP (80) + irinotecan

133

(80)

44

 

 

<0,001

50

 

 

NS

II. CDDP (80) + VDS

133

(71)

32

46

III. irinotecan

132

(85)

20

46

Yamamoto,

2004 (2)

I. CDDP (80) + docetaxel (60)

51

(40)

37 %

NS

50 s

NS

II. Irinotecan + docetaxel (60)

57

(43)

32 %

46 s

Han,

2006 (3)

I. CDDP (60) + irinotecan

41

78%

54%

 

15 m

NS

II. Irinotecan + CDDP (60)

40

80%

39%

16 m

Ohe,

2007 (4)

I. CDDP (80) + irinotecan

145

(114)

31

NS

13,9 m

NS

II. Carbo + paclitaxel

145

(117)

32

12,3 m

III. CDDP (80) + gemcitabine

146

(116)

30

14,0 m

IV. CDDP (80) + vinorelbine

145

(119)

33

11,4 m

Han,

2008 (5)  A

I. Irinotecan + cisplatin

75

87 %

38

NS

15,9 m

NS

II. Gemcitabine + vinorelbine

71

87 %

26

13,1 m



Références


(1) Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003 Feb 10;88(3):335-41.
(2) Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 2004 Jan 12;90(1):87-92.
(3) Han JY, Lim HS, Lee DH, Ju SY, Lee SY, Kim HY, et al. Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2006 Feb 15;106(4):873-80. (
4) Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007 Feb;18(2):317-23.
(5) Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 2008 Jul 15;113(2):388-95.


Retour au début de la page